Comment reveals that serum Aβ oligomer may predict treatment response in depression, suggesting further validation is needed.
Serum Aβ oligomer positivity may indicate neurodegenerative vulnerability and may be associated with poorer antidepressant treatment response in middle-aged and late-life depression. Further validation using amyloid PET, tau biomarkers, standardized treatment protocols, and longitudinal cognitive follow-up is needed.
No takes yet. Share an insight, caveat, or question.
Stjepan Škudar (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: